Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma : a phase I/II study

• Published in: Journal of molecular medicine (Berlin, Germany) Vol. 77; no. 4; pp. 393 - 398
• Main Authors: HAUENSTEIN, K, KRÖGER, J.-C, VON ROMBS, K, WAGNER, T, BERGMEISTER, H, CEIJNA, M, LOSERT, U, SCHWENDENWEIN, I, GELBMANN, W, GÜNZBURG, W. H, KARLE, P, BAGO, Z. T, HAIN, J, HENNINGER, W, PROBST, A, WALTER, I, SCHUH, M, KUNDT, G, LÖHR, M, FREUND, M, JESNOWSKI, R, LIEBE, S, HOFFMEYER, A, MÜLLER, P, PÜSCHEL, K, RENNER, M, RENZ, R, SALLER, R, SALMONS, B
• Format: Conference Proceeding Journal Article
• Language: English
• Published: Berlin Springer 01.04.1999
• Subjects: Adult; Aged; Biological and medical sciences; Biotechnology; Cell Line; Cytochrome P-450 CYP2B1 - administration & dosage; Cytochrome P-450 CYP2B1 - genetics; Drug Compounding; Female; Fundamental and applied biological sciences. Psychology; Gene therapy; Genetic Therapy; Genetic Vectors; Health. Pharmaceutical industry; Humans; Ifosfamide - administration & dosage; Ifosfamide - pharmacology; Industrial applications and implications. Economical aspects; Male; Middle Aged; Pancreatic Neoplasms - therapy; Transfection; Adenocarcinoma; Human; Ifosfamide; Cytochrome P450; Malignant tumor; Injection; Oxazaphosphinane derivatives; Treatment; Transfection; Nitrogen mustard; Phase II trial; Phase I trial; Digestive diseases; Advanced stage; Microencapsulation; Intraarterial administration; Pancreas; Gene therapy; Cell; Pancreatic disease